Beijing: Dark Horse Consulting Group (DHCG) and KunTuo Medical Research and Development (Beijing) Co Ltd (KunTuo) signed a memorandum of understanding to establish a strategic collaboration supporting biotherapeutics developers conducting clinical trials in China.

According to BERNAMA News Agency, the collaboration combines DHCG's consulting capabilities in regulatory, nonclinical, clinical, quality, supply chain, and commercial strategy with KunTuo's clinical research operations and network across China.

DHCG Founder and Chief Executive Officer, Anthony Davies, said the partnership expands the company's integrated service offerings for clients advancing programmes in China. Meanwhile, KunTuo General Manager, Linda Wang, emphasized that the collaboration would support global developers through combined expertise in regulatory strategy, drug development, and clinical trial execution.

KunTuo, established by IQVIA for the Chinese market, has delivered more than 1,000 clinical research services for pharmaceutical and medical device companies since 2011. In a statement, DHCG said the partnership is intended to provide biotherapeutics developers with an integrated pathway covering global regulatory planning and local clinical trial execution in China.

The collaboration will focus particularly on cell and gene therapy programmes, an area where KunTuo maintains dedicated clinical teams while DHCG provides expertise in regulatory requirements involving China-generated clinical data. The collaboration takes immediate effect, with joint client engagements expected to begin in the near term.